Drugs / SHR2150
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05141422 | Dec 2021 → Jan 2022 | HIV infectious disease | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04802811 | Mar → Nov 2021 | HIV infectious disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04588324 | Oct 2020 → Nov 2021 | cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR2150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04802811 ↗ |
| Action | Activate | “SHR2150 is a small molecule agonist of toll-like receptors (TLRs) 7 designed to activate antigen-presenting cells” NCT04588324 ↗ |
| Modality | Small molecule | “SHR2150 is a small molecule agonist of toll-like receptors (TLRs) 7 designed to activate antigen-presenting cells” NCT04588324 ↗ |
| Route | Oral | “three oral doses of SHR2150” NCT04588324 ↗ |
| Target | TLR7 | “Study of SHR2150 (TLR7 Agonist)” NCT04588324 ↗ |